Alterity Secures Funding Amidst Persistent R&D Losses

TL;DR

**Alterity's cash infusion buys time, but without clinical wins, more dilution is inevitable – stay cautious.**

AI Summary

ALTERITY THERAPEUTICS LTD (PRNAF) filed its 20-F for the fiscal year ended June 30, 2025, reporting a history of operating losses while actively conducting clinical trials for neurodegenerative diseases. The company successfully raised new equity funding during the 2025 financial year, which has strengthened its cash position and is expected to finance planned research and development programs for at least the next 12 months. Despite this, Alterity acknowledges the need for additional future funding, which could lead to substantial dilution for existing shareholders. The company's mission is to develop therapeutic drugs for Parkinsonian and other movement disorders, a process that is inherently expensive, time-consuming, and uncertain due to reliance on research institutions and the unpredictable nature of clinical trial outcomes. The filing highlights significant risks including potential delays in clinical trials, the challenge of retaining key personnel, and the uncertainty of market acceptance for future products.

Why It Matters

This filing reveals Alterity's ongoing financial tightrope walk, balancing significant R&D expenses with the need for continuous capital raises. For investors, the successful equity raise provides a temporary reprieve, but the long-term viability hinges on clinical trial success and avoiding further substantial dilution. Employees and customers are directly impacted by the company's ability to secure funding and advance its drug candidates, particularly in the competitive neurodegenerative disease market where breakthroughs are highly valued. The broader market watches closely as Alterity navigates the high-risk, high-reward biotech landscape, where clinical trial outcomes can dramatically shift valuations and competitive positions.

Risk Assessment

Risk Level: high — The risk level is high due to Alterity's 'history of operating losses' and the explicit statement that 'we will continue to incur losses whilst conducting clinical trials.' Furthermore, the company acknowledges the need for 'additional funding to operate our business in the future,' which 'is likely to substantially dilute our existing shareholders,' indicating ongoing financial vulnerability despite recent capital raises.

Analyst Insight

Investors should closely monitor Alterity's clinical trial progress and cash burn rate. While the recent equity raise provides short-term stability, the company's long-term success is entirely dependent on positive clinical outcomes, making it a speculative investment. Consider the potential for significant dilution before increasing exposure.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Strong

revenue Growth

Not Disclosed

Key Numbers

• 9,127,370,686 — Ordinary Shares Outstanding (As of June 30, 2025, indicating a large share base for a development-stage company.)
• 600 — Ordinary Shares per ADS (Each ADS represents 600 ordinary shares, impacting per-share valuation for U.S. investors.)
• 2025-06-30 — Fiscal Year End (The period covered by this annual report.)
• 2025-08-29 — Filing Date (Date the 20-F was filed with the SEC.)

Key Players & Entities

• ALTERITY THERAPEUTICS LTD (company) — Registrant
• David Stamler (person) — Chief Executive Officer
• The Bank of New York (company) — Depositary for ADSs
• NASDAQ Capital Market (regulator) — Exchange for ADSs
• Australian Securities Exchange (regulator) — Primary listing exchange for ordinary shares
• International Financial Reporting Standards (regulator) — Accounting standard used
• International Accounting Standards Board (regulator) — Issuer of IFRS
• Australian Accounting Standards Board (regulator) — Issuer of Australian equivalents to IFRS

FAQ

Risk Factors

• History of Operating Losses and Need for Future Funding [high — financial]: Alterity Therapeutics has a history of operating losses and will continue to incur losses while conducting clinical trials. While the company raised new equity funding in FY2025, strengthening its cash position for at least the next 12 months, it acknowledges the need for additional future funding. This future financing may not be available or could substantially dilute existing shareholders.
• Reliance on Research Institutions for Clinical Trials [medium — operational]: The company relies on external research institutions to conduct its clinical trials. There is a risk that Alterity may not be able to secure and maintain these institutions for future trials, as these institutions have their own procedures that can influence or limit the company's research and development activities.
• Uncertainty and Delays in Clinical Trials [high — operational]: Clinical trials are inherently expensive, time-consuming, and their outcomes are uncertain. The company may experience delays in its clinical trials, which could adversely affect its business and operations. There is also a risk that Alterity may not be able to complete the development of its product candidates.
• Retention of Key Personnel and Collaborations [medium — operational]: The company's research and development efforts are seriously jeopardized if it is unable to retain key personnel. Maintaining key academic and scientific collaborations is also critical for the success of its development programs.
• Keeping Pace with Technological Change and Competition [medium — market]: Alterity Therapeutics faces the risk of its technology and products becoming obsolete or non-competitive if it is unable to keep pace with technological change or the advances of its competitors in the pharmaceutical industry.

Industry Context

Alterity Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on developing treatments for neurodegenerative diseases like Parkinson's. This sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success is heavily dependent on scientific innovation, successful clinical trial outcomes, and the ability to secure substantial funding.

Regulatory Implications

As a biopharmaceutical company, Alterity is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet regulatory standards, or challenges in obtaining drug approvals represent significant risks. Compliance with evolving regulations and the complex approval process are critical for bringing any potential therapies to market.

What Investors Should Do

1. Monitor cash burn and future funding rounds.
2. Closely follow clinical trial progress and results.
3. Assess the competitive landscape and scientific advancements.

Key Dates

• 2025-06-30: Fiscal Year End — Marks the end of the reporting period for the 20-F filing.
• 2025-08-29: Filing Date of 20-F — Indicates when the company submitted its annual report to the SEC, providing updated information to investors.

Glossary

20-F

An annual report required by the U.S. Securities and Exchange Commission (SEC) for foreign private issuers, containing financial information and business operations. (This is the primary document from which this analysis is derived, providing comprehensive information about Alterity Therapeutics.)

Development Stage Company

A company that is in the early stages of its business plan and has not yet generated significant revenue or achieved profitability. (Highlights Alterity's current business model, which is focused on R&D and not yet commercialization, implying higher risk and uncertainty.)

Clinical Trials

A research study conducted with people to answer specific health questions, used to test new treatments or drugs. (Central to Alterity's business model, the success, cost, and timeline of these trials are critical to the company's prospects.)

Equity Capital Raisings

The process of raising funds by selling shares of the company to investors. (Indicates how Alterity has funded its operations and R&D, and highlights the potential for future dilution.)

Dilution

The reduction in the ownership percentage of a shareholder when a company issues new shares. (A significant risk for existing shareholders, as future funding needs may lead to the issuance of more shares, reducing their proportional ownership.)

Year-Over-Year Comparison

The 20-F for the fiscal year ended June 30, 2025, indicates that Alterity Therapeutics successfully raised new equity funding, strengthening its cash position compared to previous periods where funding may have been more constrained. While the company continues to operate at a loss, as is typical for development-stage biotechs, the recent funding provides a runway for at least the next 12 months. New risks highlighted or emphasized include the ongoing reliance on research institutions and the critical need for retaining key personnel, alongside the persistent risk of substantial shareholder dilution from future financing needs.

Filing Documents

• ea0254438-20f_alterity.htm (20-F) — 1958KB
• ea025443801ex12-1_alterity.htm (EX-12.1) — 10KB
• ea025443801ex12-2_alterity.htm (EX-12.2) — 10KB
• ea025443801ex13-1_alterity.htm (EX-13.1) — 4KB
• ea025443801ex13-2_alterity.htm (EX-13.2) — 4KB
• ea025443801ex15-1_alterity.htm (EX-15.1) — 2KB
• ea025443801ex15-2_alterity.htm (EX-15.2) — 1KB
• image_001.jpg (GRAPHIC) — 97KB
• 0001213900-25-082027.txt ( ) — 8737KB
• athe-20250630.xsd (EX-101.SCH) — 106KB
• athe-20250630_cal.xml (EX-101.CAL) — 48KB
• athe-20250630_def.xml (EX-101.DEF) — 347KB
• athe-20250630_lab.xml (EX-101.LAB) — 659KB
• athe-20250630_pre.xml (EX-101.PRE) — 373KB
• ea0254438-20f_alterity_htm.xml (XML) — 1345KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No This Annual Report on Form 20-F is incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-228671, 333-248980 and 333-251073) and our Registration Statements on Form F-3 (File No. 333-274816). INTRODUCTION Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) was incorporated under the laws of the Commonwealth of Australia on November 11, 1997. Our mission is to develop therapeutic drugs designed to treat neurogenerative diseases, currently focusing on Parkinsonian and other movement disorders. The principal listing of our ordinary shares and listed options to purchase our ordinary shares is on the Australian Securities Exchange, or ASX. Since September 5, 2002, our American Depository Shares, or ADSs, have traded on the NASDAQ Capital Market under the symbol "PRAN." On April 8, 2019, we changed our name to Alterity Therapeutics Limited and our ADSs have traded under the symbol "ATHE" since that date. The Bank of New York, acting as depositary, issues American Depository Receipts, or ADRs, each of which evidences an ADS, which in turn represents 600 of our ordinary shares. As used in this annual report, the terms "we," "us," "our", "the Company", "the Group" and "Alterity" mean Alterity Therapeutics Limited and its subsidiaries, unless otherwise indicated. Our consolidated financial statements appearing in this annual report are prepared in Australian dollars and in accordance with the International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB and Australian equivalents to International Financial Reporting Standards as issued by the Australian Accounting Standards Board. Australian Disclosure Requirements Our ordinary shares are primarily quoted on the Australian Securities Exchange ("A

Forward-Looking Statements

Forward-Looking Statements Except for the historical information contained in this annual report, the statements contained in this annual report are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995, as amended, with respect to our business, financial condition and results of operations. Such forward-looking statements reflect our current view with respect to future events and financial results. We urge you to consider that statements which use the terms "anticipate," "believe," "do not believe," "expect," "plan," "intend," "estimate," and similar expressions are intended to identify forward-looking statements. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity, or our achievements, or industry results, to be materially different from any future results, performance, levels of activity, or our achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to publicly release any update or revision to any forward-looking statements to reflect new information, future events or circumstances, or otherwise after the date hereof. We have attempted to identify significant uncertainties and other factors affecting forward-looking TABLE OF CONTENTS Page PART I 1 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 1 I

Risk Factors

Risk Factors 1 ITEM 4. INFORMATION ON THE COMPANY 24 A. History and Development of the Company 24 B. Business Overview 25 C. Organizational Structure 37 D. Property, Plant and Equipment 37 ITEM 4A. UNRESOLVED STAFF COMMENTS 38 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 38 A. Operating Results 38 B. Liquidity and Capital Resources 41 C. Research and Development, Patents and Licenses 43 D. Trend Information 44 E. Critical Accounting Estimates 44 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 45 A. Directors and Senior Management 45 B. Compensation 47 C. Board Practices 54 D. Employees 56 E. Share Ownership 57 F. Disclosure of a registrant's action to recover erroneously awarded compensation 60 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 61 A. Major Shareholders 61 B. Related Party Transactions 61 C. Interests of Experts and Counsel 61 ITEM 8. FINANCIAL INFORMATION 62 A.

Financial Statements and Other Financial Information

Financial Statements and Other Financial Information 62 B. Significant Changes 62 ITEM 9. THE OFFER AND LISTING 62 A. Offer and Listing Details 62 B. Plan of Distribution 6 2 C. Markets 62 D. Selling Shareholders 63 E.

Dilution

Dilution 63 F. Expenses of the Issue 63 ITEM 10. ADDITIONAL INFORMATION 63 A. Share Capital 63 B. Memorandum and Articles of Association 63 C. Material Contracts 64 D. Exchange Controls 64 E. Taxation 64 F. Dividends and Paying Agents 71 G. 71 H. Documents on Display 71 I. Subsidiary Information 71 J. Annual Report to Security Holders 71 i ITEM 11.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 71 ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 72 PART II 73 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 73 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 73 ITEM 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 73 ITEM 16. RESERVED 74 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT 74 ITEM 16B. CODE OF ETHICS 74 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 74 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 74 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 74 ITEM 16F. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT 75 ITEM 16G. CORPORATE GOVERNANCE 75 ITEM 16H. MINE SAFETY DISCLOSURE 75 ITEM 16I DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 75 ITEM 16J INSIDER TRADING POLICIES 75 ITEM 16K CYBER SECURITY 75 PART III 77 ITEM 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 77 ITEM 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 77 ITEM 19. EXHIBITS 79

SIGNATURES

SIGNATURES 80 ii PART I

IDENTITY

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not applicable.

OFFER

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE Not applicable.

KEY

ITEM 3. KEY INFORMATION A. [Reserved] B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D.

Risk Factors

Risk Factors Investing in our securities involves a high degree of risk and uncertainty. You should carefully consider the risks and uncertainties described below before investing in our securities. Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also adversely affect our business. If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could be harmed. In that case, the daily price of our securities could decline, and you could lose all or part of your investment. These risk factors include: Risks Related to Our Financial Condition We have a history of operating losses and will continue to incur losses whilst conducting clinical trials. However, we also have a history of successfully raising funds via equity capital raisings, and as a result, we have a strong cash position for the fiscal year ended June 30, 2025. The continuing viability of the Group is subject to its ability to raise additional capital to finance the continuation of its planned research and development programs, maintaining implemented cost containment and deferment strategies, and successfully commercializing its initiatives. The Group successfully raised new equity funding during the 2025 financial year to enable progression of its planned research and development programs for at least the next 12 months. We will still need additional funding to operate our business in the future; such funding may not be available or, if it is available, such financing is likely to substantially dilute our existing shareholders. Risks Related to Our Business We are a development stage company engaged in the development of pharmaceutical products and our success is uncertain. We rely on research institutions to conduct our clinical trials and we may not be able to secure and maintain research institutions to conduct our future trials. The institutions that we work with have their own li

View Full Filing

View this 20-F filing on SEC EDGAR